Similarly, four of eight patients with metastatic BC carrying BRCA1/2 mutations who were treated with PARPi or platinum developed BRCA reversal mutations, and a significant increase in RAD51 expression after drug resistance was found by detecting changes in protein expression in tumor tissues before and after drug resistance (Waks et al., 2020). Here, RAD51 is linked to neoplasm.